20 results about "Occludin" patented technology

The invention discloses a probiotic which is derived from human milk and has the effects of resisting oxidation, resisting inflammation, protecting tissues and protecting intestinal barriers and application of the probiotic. Lactobacillus paracasei DPUMW-M14-9 is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, and the preservation number is CCTCC M 20252990. The strain has the characteristics of acid resistance, bile resistance, strong oxidation resistance, high surface hydrophobicity, self-aggregation capability and the like. The lactobacillus paracasei DPUMW-M14-9 can effectively adhere to epithelial cells, promote cell proliferation and regulate and control the process of a cell cycle. The bacterial strain can be used for inhibiting proinflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) induced by lipopolysaccharide (LPS) and repairing tight junction proteins (ZO-1, Occludin and Claudin-1) at the same time, so that the integrity of epithelial cells is enhanced.

The invention discloses recombinant lactobacillus casei for expressing sialyltransferase ST6GALNAC1, and belongs to the technical field of genetic engineering and microorganisms. The recombinant bacterium is obtained by cloning an ST6GALNAC1 gene to a pPG612 vector and electrically transforming the ST6GALNAC1 gene into lactobacillus casei ATCC393. Experiments show that the engineering bacterium can significantly enhance glycosylation modification of intestinal mucoprotein MUC2, improve expression of tight junction proteins (ZO-1, Occludin and Claudin-1), inhibit activation of a p38 / MAPK inflammation pathway and regulate an intestinal flora structure, so that intestinal injury and systemic inflammatory response caused by salmonella are effectively relieved. The invention provides a strain basis and technical support for developing a novel oral microecological preparation.

The present application relates to the use of vascular BACE1 as a therapeutic target for diseases related to cerebral small vessel injury. Specifically, it relates to the use of a substance that reduces the expression level of the beta-secretase (BACE1) gene and / or an inhibitor of the enzymatic activity of BACE1 protein in the preparation of a drug for treating or alleviating cerebrovascular disease, wherein the disease related to cerebral small vessel injury is preferably Alzheimer's disease, amyloid cerebral small vessel disease, and vascular dementia. The inventors have found that an increase in the content of BACE1 can cleave the tight junction protein Occludin, resulting in the degradation and loss of tight junction proteins between vascular endothelial cells, causing the structure and function of the blood-brain barrier to be damaged, ultimately leading to cerebral microbleeds and cognitive dysfunction and other pathological phenotypes of diseases related to cerebral small vessel injury; inhibition of the enzymatic activity of BACE1 can improve these pathological phenotypes of diseases related to cerebral small vessel injury.

The invention discloses lactobacillus helveticus capable of relieving rheumatoid arthritis and application of the lactobacillus helveticus, and belongs to the technical field of microorganisms. A strain of lactobacillus helveticus CCFM1501 is screened out, the lactobacillus helveticus CCFM1501 can produce cell wall protease, amino-peptidase and aromatic transaminase at high yield, and has the effect of relieving rheumatoid arthritis, and the specific effects are that the thickness of a posterior claw of a rat with rheumatoid arthritis is reduced, and knee joint injury is improved; the content of proinflammatory cytokines in the serum of rheumatoid arthritis rats is reduced, the content of anti-inflammatory cytokines IL-10 in the serum of the rheumatoid arthritis rats is increased, the content of arthritis specific antibodies in the serum of the rheumatoid arthritis rats is reduced, the mRNA relative expression quantity of colonic tight junction proteins ZO-1 and Occludin in the rheumatoid arthritis rats is increased, and the anti-inflammatory activity of the rheumatoid arthritis rats is improved. The content of acetic acid and butyric acid in excrement of rats with rheumatoid arthritis is increased.

Provided are a probiotic composition for preventing and treating intestinal inflammation and a use thereof. The probiotic composition for preventing and treating intestinal inflammation comprises a Lactobacillus acidophilus LA85 strain and a Bifidobacterium longum subsp. BL36 strain. Provided are a new probiotic formulation method and a new strategy for preventing and treating intestinal inflammation. It has been found that the LA85 strain and the BL36 strain can cooperate with each other, promote each other, have a synergistic effect in preventing and treating intestinal inflammation, can reduce the concentrations of the pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in the serum of mice, and increase the concentration of the anti-inflammatory cytokine IL-10; can increase the concentration of urolithin A in the serum of mice and significantly reduce the concentration of reactive oxygen species in the serum; and can significantly increase the levels of the intestinal barrier indicators tight junction protein-1, tight junction protein, and Claudin-1 in the serum of mice.

The invention discloses application of ursolic acid or ursolic acid derivatives in preparation of chicken coccidiosis-resistant feed or chicken coccidiosis-resistant drugs, and relates to the technical field of biological medicines. The chicken coccidiosis protozoon is chicken eimeria tenella, the ursolic acid derivative is oleanolic acid, and the ursolic acid derivative and ursolic acid are isomers. The chicken coccidiosis-resistant feed or the chicken coccidiosis-resistant drug has at least one of the following functions: reducing the cecum lesion value and the number of oocysts, and inhibiting the depth increase of crypts induced by chicken coccidiosis; weight loss caused by chicken coccidiosis infection is relieved; the expression of inflammatory factors caused by chicken coccidiosis infection is reduced, and the inflammatory factors comprise IL-6, IL-8, TNF-alpha and IFN-gamma; the expression of tight junction protein after chicken coccidiosis infection is promoted, and the tight junction protein comprises ZO-1, Claudin-1 and Occludin. The traditional Chinese medicine composition has the advantages of low toxicity, low residue, good anti-chicken coccidiosis effect, simplicity in preparation, suitability for batch production and the like.

The application discloses a recombinant lactobacillus casei expressing sialyltransferase ST6GALNAC1, and belongs to the field of genetic engineering and microbial technology. The recombinant bacterium is obtained by cloning the ST6GALNAC1 gene into a pPG612 vector and electrotransforming the ST6GALNAC1 gene into lactobacillus casei ATCC393. Experiments show that the engineering bacterium can significantly enhance glycosylation modification of intestinal mucus protein MUC2, improve expression of tight junction proteins (ZO-1, Occludin and Claudin-1), inhibit activation of a p38 / MAPK inflammatory pathway, and regulate intestinal flora structure, thereby effectively relieving intestinal injury and systemic inflammatory response caused by salmonella. The application provides a strain basis and technical support for development of a new type of oral microecological preparation.

The invention relates to the technical field of natural medicine application, and discloses a maggot fatty acid active ingredient composition and application thereof, and a high-purity fatty acid composition with a specific ingredient spectrum is obtained through an optimized supercritical CO2 extraction and molecular distillation combined technology. The composition is proved to be capable of treating UC through a multi-target and multi-channel synergistic effect for the first time: proinflammatory factors are reduced by inhibiting classical inflammatory pathways such as NF-kappa B, oxidative stress is relieved by activating an Nrf2 / HO-1 antioxidant pathway, expression of intestinal tight junction proteins (such as ZO-1 and Occludin) is specifically up-regulated so as to repair an intestinal mechanical barrier, and the UC treatment effect is improved. Meanwhile, the metabolism of short-chain fatty acid of intestinal flora is regulated so as to improve the microecology of the intestinal tract. Animal experiments show that the curative effect of the composition is superior to that of a positive drug 5-ASA, the side effect is small, and a brand-new solution derived from natural drugs is provided for solving the UC treatment dilemma.

The invention provides application of astaxanthin in preparation of medicines for preventing and treating intestinal dysfunction and intestinal flora imbalance related to severe acute pancreatitis or repairing intestinal mucosal barrier. In-vivo experiments prove that the astaxanthin can significantly improve SAP-induced intestinal barrier injury, reduce the activity of serum diamine oxidase (DAO), repair a jejunum villus structure and up-regulate the expression of tight junction proteins (ZO-1, Occludin and Claudin); the mechanism relates to inhibition of local inflammatory response and oxidative stress, and specific correction of intestinal flora disorder, including recovery of proportion balance of phylum firmicalis and bacteroides, and improvement of abundance of beneficial bacteria such as lactobacillus murine and ruminococcus; the invention provides a new strategy for clinical treatment of SAP complicated with intestinal failure.

The invention relates to the technical field of functional food processing, in particular to a method for enhancing intestinal barrier function regulating activity of galactooligosaccharide based on collagen peptide Maillard coupling and application of the method. According to the method for enhancing the intestinal barrier regulating activity of the galactooligosaccharide based on Maillard coupling of the collagen peptide, provided by the invention, the biological effect of the galactooligosaccharide in the aspect of regulating the intestinal barrier function can be remarkably improved; meanwhile, the obtained Maillard conjugate has remarkable advantages in the aspects of promoting mucous secretion of goblet cells, up-regulating expression of tight junction proteins ZO-1 and Occludin and reducing intestinal permeability. The method provided by the invention is simple and convenient to operate, industrialization is easy to realize, the obtained product can be used as a functional component related to intestinal health to be applied to the fields of food, functional food and the like, and the application value of galactooligosaccharide can be effectively improved.

The invention discloses application of Pediococcus pentosaceus PPSJ001 or peptidoglycan of the Pediococcus pentosaceus PPSJ001 in preparation of a product for preventing or treating intestinal inflammatory diseases, and the Pediococcus pentosaceus PPSJ001 is Pediococcus pentosaceus. The invention further discloses a preparation method of the Pediococcus pentosaceus PPSJ001 and a preparation method of the Pediococcus pentosaceus PPSJ001. According to the application research of the pediococcus pentosaceus PPSJ001 and peptidoglycan thereof in DSS-induced acute and chronic colitis mouse models, prophylactic or therapeutic gavage can obviously reduce the inflammation degree, relieve weight loss, restore the colon length and improve pathological damage of colon tissue. The pediococcus pentosaceus PPSJ001 can be used for promoting the expression of tight junction proteins ZO-1 and Occludin and mucoprotein Muc2 and improving the barrier function of intestinal mucosa. The key functional component is cell wall peptidoglycan, and the peptidoglycan can remarkably relieve the colitis disease in vivo, promote polarization of macrophages to a CD206 + M2 type in vitro and improve expression of anti-inflammatory related genes Arg1. Based on the unique functions, the pediococcus pentosaceus PPSJ001 or peptidoglycan thereof can be coordinated or complemented with other micro-ecological regulation means, and has a wide application prospect in medicine preparation.

The invention provides an application of fructus psoraleae polysaccharide in preparation of a medicine or health food for regulating an intestinal barrier function. Specifically, the fructus psoraleae polysaccharide acts on an intestinal tract. In the intestinal tract action process, the fructus psoraleae polysaccharide effectively improves damaged intestinal tract barrier repair; the number of CD4 + and CD8 + T cells in intestinal tracts is increased, and the immune barrier of the intestinal tracts is improved; according to the present invention, the expression of tight junction proteins Claudin-1, Occludin and ZO-1 can be promoted, the intestinal mechanical barrier can be repaired and enhanced, and the polypeptide can be used for preventing, relieving or treating intestinal barrier damage, has excellent performance in the regulation of the intestinal barrier function, and has good application prospects.

The invention relates to an application of probiotics, and provides an application of clostridium butyricum MIYAIRI 588 viable bacteria (CBM 588) in preparation of a preparation for preventing and treating calcium oxalate kidney stone, and particularly relates to an application of the clostridium butyricum MIYAIRI 588 viable bacteria (CBM 588) in preparation of a preparation for preventing and treating calcium oxalate kidney stone. The formulation can be an orally administered formulation, and the viable bacteria can be dispersed in an aqueous carrier to form a solution or suspension. Animal model experiments show that the clostridium butyricum treatment can reduce kidney crystal or calcium salt deposition related characterization, reduce serum creatinine and urea nitrogen, regulate intestinal flora structure, improve expression of ileum tight junction protein ZO-1 and occludin, reduce serum endotoxin level and reduce the content of glycohyodeoxycholic acid in excrement, serum and kidney, and can be used for treating the kidney and the kidney. A novel preparation application is provided for preventing and treating the calcium oxalate kidney stone.

The invention discloses a lactobacillus johnsonii YS my4 strain with a cryptosporidium infection resisting effect and application of the lactobacillus johnsonii YS my4 strain. The preservation number of the YS my4 strain is CCTCC (China Center For Type Culture Collection) M 20253011. The strain disclosed by the invention has the characteristics of cholate resistance, intestinal juice resistance, strong adhesiveness and capability of inhibiting salmonella and staphylococcus aureus. In addition, the strain has no hemolytic rings, and the strain has no influence on body indexes and can increase the body weight after gavage of suckling rats, so that the strain is proved to be high in safety and can be applied to the fields of medicine and food. According to the invention, the YS my4 strain is intragastrically fed to a pseudo-sterile suckling mouse infected by cryptosporidium parvum, and it is found that the strain can activate immune defense of the intestinal tract of a host by improving the MAPK phosphorylation level of the host in the state of cryptosporidium parvum infection, so that the insect loading amount of the cryptosporidium parvum is remarkably reduced; meanwhile, the YS my4 strain can improve the expression level of tight junction proteins Occludin and CLDN4, relieve pathological damage of ileum tissues and improve the intestinal barrier function, and has important application value in prevention and treatment of cryptosporidium parvum infection.

The invention belongs to the technical field of biological medicine, and particularly relates to a composition containing salty taste enhancing peptide and naringenin and application of the composition. The active ingredients of the composition are composed of salty taste enhancing peptide and naringenin in a mass ratio of 100: 1. Animal experiment results show that the composition can effectively improve intestinal flora imbalance of senescence diabetes model mice, up-regulate expression of tight junction proteins ZO-1 and Occludin, repair intestinal barriers, increase the ratio of mycophylum to bacteroides, promote growth of beneficial bacteria such as micrococcus verrucosus and actinomycetes, especially promote growth of Ackerman's bacteria and bifidobacteria, and improve the immunity of senescence diabetes mellitus mice. The intestinal flora structure deviation is reversed, and the content of short-chain fatty acid in the intestinal tract is remarkably increased. The invention provides a novel prebiotic for regulating intestinal flora, and has a good application prospect.

The invention discloses an application of ginsenoside Ro in preparation of a medicine for treating cerebral ischemia-reperfusion injury. According to the application disclosed by the invention, by preparing a middle cerebral artery occlusion / reperfusion (MCAO) mouse model, the ginsenoside Ro is found to be capable of reducing the cerebral infarction volume of the model mouse, improving the pathological injury of brain tissues and increasing the cerebral blood flow at the ischemic side. Meanwhile, the ginsenoside Ro up-regulates the expression of brain tissue tight junction proteins ZO-1 and Occludin, inhibits the expression of matrix metalloproteinase MMP-9 / 2, reduces the leakage amount of Evans blue, and improves the blood brain barrier (BBB) dysfunction. Besides, by preparing an oxygen glucose deprivation / reperfusion (OGD / R) induced mouse brain microvascular endothelial cell line 3 (bEnd.3) cell model, it is found that the ginsenoside Ro can improve the damage of the barrier function of the bEnd.3 cell induced by the OGD / R, it is proved that the ginsenoside Ro can be used for the novel medical application of treating the cerebral arterial thrombosis, and the ginsenoside Ro has a wide application prospect.

This invention provides the use and products of L-glutamine in the treatment or prevention of intestinal barrier dysfunction, belonging to the field of pharmaceutical technology. An animal model was established using the tail suspension method to simulate a microgravity environment to induce intestinal barrier dysfunction, demonstrating that L-glutamine can significantly improve intestinal barrier function. Its beneficial effects include upregulating the expression of tight junction proteins Claudin-1, Occludin, and ZO-1 in intestinal tissue, directly repairing the intestinal epithelial physical barrier; and downregulating the expression of NF-κB p65 protein, inhibiting NF-κB signaling pathway-related inflammatory responses. Furthermore, the application of L-glutamine can alleviate liver pathological changes secondary to intestinal barrier dysfunction. This invention provides a novel nutritional intervention strategy for the repair of intestinal barrier dysfunction. The product can be an oral pharmaceutical preparation or a special medical purpose food, and is safe, effective, and has significant application prospects.

The invention discloses application of myricetin in proliferation and differentiation of intestinal stem cells, and belongs to the field of organoid culture. After the organ-like model is treated by myricetin, the relative expression quantity of Lgr5 mRNA is remarkably increased, which indicates that the model can respond to intervention of myricetin, up-regulate expression of an intestinal stem cell marker Lgr5, and contribute to proliferation and tissue repair of intestinal stem cells. Immunofluorescence detection shows that the protein expression intensity of the myricetin group MUC2 is enhanced, which proves that the model can verify the promotion effect of myricetin on goblet cell differentiation and mucus secretion and improve the intestinal barrier function. QPCR detection proves that after myricetin treatment, the relative expression quantity of mRNA closely connected with related genes ZO-1, Occludin and Claudin-1 is remarkably increased, which indicates that the organ model can evaluate the protection and strengthening effects of myricetin on intestinal epithelium close connection, and has potential application value in treatment of intestinal barrier injury related diseases.

The present application relates to the technical field of biopharmaceuticals, and particularly relates to a siRNA targeting ADAM17 gene based on intestinal barrier repair and application thereof in improving visceral hypersensitivity of IBS. The siRNA silences ADAM17 expression, inhibits abnormal cleavage of IL-10 receptor alpha subunit (IL-10RA) on the membrane of intestinal epithelial cells, maintains the integrity of the membrane-bound IL-10 receptor, restores IL-10 protective signaling, up-regulates tight junction proteins such as ZO-1 and Occludin, reduces intestinal permeability, repairs intestinal mucosal barrier, and finally improves colorectal distension-induced pain threshold and relieves visceral hypersensitivity. Animal model experiments show that the siRNA can significantly reduce the expression of ADAM17 protein in the colon, improve the structure and function of the barrier, and increase the pain threshold, and has application prospects as a new molecular targeted treatment for IBS.

The invention discloses a composition for treating ulcerative colitis and an application of the composition. The composition is prepared from dendrobium huoshanense polysaccharide and clostridium edwardsii Marsele-P3397, and the composition is prepared from the dendrobium huoshanense polysaccharide and the clostridium edwardsii Marsele-P3397. The dendrobium huoshanense polysaccharide can promote the clostridium edwardsii to generate short-chain fatty acid, the synergistic effect of the dendrobium huoshanense polysaccharide and the clostridium edwardsii can reduce release of proinflammatory factors TNF-alpha and IL-1beta and up-regulate expression of tight junction proteins ZO-1 and Occludin so as to repair the intestinal epithelial barrier and regulate the intestinal flora structure, and then the ulcerative colitis treatment effect is remarkably improved. The invention breaks through the intervention mode of a single drug or probiotics, constructs a'natural product-intestinal beneficial bacteria 'synergistic system, makes up the limitation of single intervention, provides experimental support for joint development of genuine traditional Chinese medicine active ingredients and probiotics, has important clinical application value, is high in safety and adapts to long-term intervention.